Bristol Imperial MDMA in Alcoholism Study
Brief Summary
The Safety, Tolerability and Role of MDMA-Assisted Psychotherapy for the treatment of detoxified patients with Alcohol Use Disorder.
Condition or Disease
- Alcohol Use Disorder
Phase
Study Design
| Study type: | Interventional |
|---|---|
| Status: | Unknown status |
| Study results: | No Results Available |
| Age: | 18 Years to 65 Years (Adult, Older Adult) |
| Enrollment: | 20 () |
| Funded by: | Other |
Masking |
|
Clinical Trial Dates
| Start date: | Apr 18, 2018 | |
|---|---|---|
| Primary Completion: | Jun 12, 2020 | |
| Completion Date: | Jun 12, 2020 | |
| Study First Posted: | Nov 12, 2019 | |
| Results First Posted: | Aug 30, 2020 | |
| Last Updated: | Nov 12, 2019 |
Sponsors / Collaborators
Lead Sponsor:
N/A
Responsible Party:
N/A
Location
This is an open label within-subject feasibility study, in 20 patients with Alcohol Use Disorder who have recently undergone detoxification. All patients will receive MDMA-Assisted drug therapy. This study aims to assess if MDMA-Assisted Psychotherapy can be delivered safely and can be tolerated by patients with alcohol use disorder post-detoxification. Outcomes regarding abstinence from alcohol, quality of life and psychosocial functioning will be evaluated.
Eligibility Criteria
| Sex: | All |
|---|---|
| Minimum Age: | 18 |
| Maximum Age: | 65 |
More Details
| NCT Number: | NCT04158778 |
|---|---|
| Acronym: | BIMA |
| Other IDs: | BIMA2016|2016-002547-42 |
| Study URL: | https://ClinicalTrials.gov/show/NCT04158778 |
Last updated: Jun 16, 2022